Meloxicam , ≥98% , 71125-38-7
Synonym(s):
4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide;4-Hydroxy-2-methyl-N-(5-methyl-2-thiazoyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide;Meloxicam;Meloxicam - CAS 71125-38-7 - Calbiochem
CAS NO.：71125-38-7
Empirical Formula: C14H13N3O4S2
Molecular Weight: 351.4
MDL number: MFCD00868752
EINECS: 615-253-8
| Pack Size | Price | Stock | Quantity |
| 5G | RMB60.80 | In Stock |
|
| 10g | RMB99.20 | In Stock |
|
| 25G | RMB188.80 | In Stock |
|
| 100g | RMB569.60 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 255 °C |
| Density | 1.613±0.06 g/cm3(Predicted) |
| storage temp. | 2-8°C |
| solubility | DMSO: soluble |
| form | Off-white solid |
| pka | 4.08 in water; 4.24 ± 0.01 in water/ethanol (1:1); 4.63 ± 0.03 in water/ethanol (1:4) |
| color | yellow |
| Water Solubility | practically insoluble in water(0.154 mg/mL), with higher solubility observed in strong acids and bases. |
| Merck | 14,5826 |
| BCS Class | 2(CLogP),
4 (LogP) |
| Stability: | Stable. Incompatible with strong oxidizing agents. |
| InChI | InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,18H,1-2H3,(H,15,16,19) |
| InChIKey | ZRVUJXDFFKFLMG-UHFFFAOYSA-N |
| SMILES | S1(=O)(=O)C2=CC=CC=C2C(O)=C(C(NC2=NC=C(C)S2)=O)N1C |
| EPA Substance Registry System | 2H-1,2-Benzothiazine-3-carboxamide, 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-, 1,1-dioxide (71125-38-7) |
Description and Uses
Known as a nonsteroidal anti-inflammatory drug (NSAID), Meloxicam is commonly used to treat pain or inflammation caused by rheumatoid arthritis and osteoarthritis in adults. It is also used to treat juvenile rheumatoid arthritis in children who are at least 2 years old. It is effective to reduce pain, inflammation, swelling, and stiffness of the joints. Developed by Boehringer-Ingelheim, Meloxicam is a derivative of oxicam that can relieve the symptoms of arthritis, primary dysmenorrhea, fever with analgesic and antipyretic properties. Meloxicam was approved for use in April 2000.
Anti-inflammatory effects of meloxicam function by inhibiting the prostaglandin synthetase (cyclooxygenase 1 and 2) which results in a decrease of the synthesis of prostaglandins. As prostaglandins are chemicals that contribute to inflammation especially within joints, which leads to the common symptoms of pain, tenderness, and swelling associated with arthritis, inhibition of their synthesis can be associated with the analgesic and antipyretic effects of meloxicam. As a result, inflammation and its accompanying symptoms are reduced. Meloxicam starts to relieve pain about 30 to 60 minutes after administration.
Meloxicam is a preferential cyclooxygenase (COX-2) inhibitor that used for symptomatic treatment of arthritis and osteoarthritis. Sudoxicam and Meloxicam are nonsteroidal anti-inflammatory drugs (NSAIDs) from the enol-carboxamide class.
Safety
| Symbol(GHS) |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P264-P270-P301+P310-P405-P501 |
| Hazard Codes | Xn,T |
| Risk Statements | 22-36/37/38-25 |
| Safety Statements | 26-45-60-36/37 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | DL0702000 |
| HazardClass | 6.1 |
| PackingGroup | III |
| HS Code | 29349990 |
| Hazardous Substances Data | 71125-38-7(Hazardous Substances Data) |
| Toxicity | LD50 orally in mice: 470 mg/kg (Trummlitz, 1980) |
